With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

CSL shares are down roughly 40% since acquiring Vifor in August 2022, an iron deficiency and kidney disease business and the largest acquisition in its history. However, several other factors have ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

CSL Behring has identified what it will take to win in a major autoimmune market. Ahead of a potential approval of argenx’s rival drug, the company surveyed people with chronic inflammatory ...

"PROTINUS" (lat. forward, further") is the name of the project with which the biopharmaceutical company CSL Behring will significantly increase the production capacity of immunoglobulin at its site.